/
QNTM
$3.46+$0.00 (+0.00%)prev close
Change$-0.81
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$145.3
0M shares
52-week range
$2.07 – $21.00
7% from low
Exchange
NASDAQ
CS
Quantum Biopharma Ltd. Class B Subordinate Voting Shares
Quantum BioPharma Ltd is a biopharmaceutical company dedicated to building a portfolio of inventive assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, it is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, which represents loans secured by residential or commercial property.
www.quantumbiopharma.com- Employees
- 7
- IPO / List date
- Jun 7, 2018
Held by traders on TradeandTell
No one on the platform currently holds QNTM.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in QNTM as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2024-08-15 | 20-for-1 |
| 2019-10-16 | 1-for-201reverse |
Recent trades on TradeandTell
No one on the platform has traded QNTM yet.
